Navigation Links
Edimer Pharmaceuticals and CMC Biologics Announce Agreement to Manufacture EDI200 Recombinant Protein
Date:9/9/2010

CAMBRIDGE, Mass. and BOTHELL, Wash., Sept. 9 /PRNewswire/ -- Edimer Pharmaceuticals and CMC Biologics today announce the execution of a manufacturing contract to support the development of EDI200, a clinical-stage recombinant protein for the treatment of X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), a rare genetic disease with orphan designation in the USA and Europe.

(Logo:  http://photos.prnewswire.com/prnh/20100909/SF59797LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100909/SF59797LOGO)

(Logo:  http://photos.prnewswire.com/prnh/20100824/SF54816LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100824/SF54816LOGO)

CMC Biologics was selected by Edimer for their lead product due to its depth of expertise in protein development, analytical development and its cGMP manufacturing capabilities.

Neil Kirby, Ph.D., Edimer CEO, commented, "CMC's extensive experience in the GMP manufacture of therapeutic proteins makes them an ideal company to help us move this product forward. We believe that this product has the potential for making a difference in individuals' lives that currently have no available therapeutic options."

Gustavo Mahler, Ph.D., CMC Biologics Chief Operating Officer noted, "CMC is delighted to be able to assist Edimer in the development and production of this orphan protein. Our two teams are working together in an open and collaborative manner and we are excited about the project's potential."

About EDI200

Ectodysplasin-A1 (EDA-A1) is a signaling protein expressed in healthy individuals that is involved in the formation of sweat glands, teeth, hair and certain glandular structures. This protein is missing in patients with XLHED.  EDI200 is a form of EDA-A1 being developed by Edimer as a treatment for certain patients with XLHED.  EDI200 has been shown to substitute for lack of functional EDA-A1 protein in mouse and dog models of XLHED.

About Edimer Pharmaceuticals

Edimer Pharmaceuticals (www.edimerpharma.com)

Edimer is dedicated to deliver a significant and durable improvement in the health and quality of life to future generations affected by XLHED. Edimer was established in 2009 based on research conducted at the University of Lausanne, Switzerland. Edimer's lead product candidate, EDI200, represents the first of a new class of molecules designed to correct a developmental disorder in a pediatric population.

About CMC

CMC Biologics (www.cmcbio.com) is a leading contract development and manufacturing organization that provides fully integrated biopharmaceutical development and manufacturing services to clients around the world, from its facilities in Copenhagen, Denmark, and Seattle, WA.  The company specializes in custom services for the scale-up and cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials and in-market production.  CMC Biologics' wide range of integrated services includes cell line development using its proprietary CHEF1® system, process development and comprehensive analytical testing.  CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers both stirred tank and perfusion production processes.  


'/>"/>
SOURCE Edimer Pharmaceuticals; CMC Biologics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Transdel Pharmaceuticals to Present at Rodman & Renshaw 12th Annual Healthcare Conference
2. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare and Baird Global Healthcare Conferences
3. Access Pharmaceuticals Presents at American Chemical Society Annual Fall Meeting in Boston, MA
4. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
5. NanoSmart™ Pharmaceuticals, Inc. Receives Patent Allowance for Tumor Targeting Platform Technology
6. CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc.
7. Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010
8. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010
9. Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients
10. Amira Pharmaceuticals Hits Two Development Milestones Related to FLAP Inhibitor Program
11. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Global demand for enzymes is ... 2020 to $7.2 billion.  This market includes enzymes ... products, biofuel production, animal feed, and other markets) ... biocatalysts). Food and beverages will remain the largest ... consumption of products containing enzymes in developing regions.  ...
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)... BOSTON , June 27, 2016   Ginkgo ... biology to industrial engineering, was today awarded as ... a selection of the world,s most innovative companies. ... at scale for the real world in the ... organism engineers work directly with customers including Fortune ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle ... people with peritoneal or pleural mesothelioma. Their findings are the subject of a new ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma ...
Breaking Biology Technology:
(Date:6/21/2016)... , June 21, 2016 NuData Security announced ... new role of principal product architect and that ... director of customer development. Both will report directly ... officer. The moves reflect NuData,s strategic growth in ... to high customer demand and customer focus values. ...
(Date:6/9/2016)... , June 9, 2016  Perkotek an innovation leader in attendance control systems is ... log work hours, for employers to make sure the right employees are actually signing ... http://photos.prnewswire.com/prnh/20160609/377486LOGO ... ... ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... project, for the , Supply and Delivery of ... Infrastructure , to Decatur , ... Management Solutions. Numerous renowned international vendors participated in the tendering ... selected for the most compliant and innovative solution. The contract ...
Breaking Biology News(10 mins):